As part of a wider conversation about the state of UK life sciences, recruiter Michael Woodhead and commercial strategy specialist Kaiser Karamdad turned their attention to a question that sits behind many of the sector's hiring challenges: why does the UK - with its world-class science base and high proportion of STEM graduates - struggle so consistently to scale its life sciences workforce? This is the third article in the series.
I think it is fair to say that the United Kingdom punches well above its weight in life sciences. It has world-class academic institutions, a strong track record in early-stage company formation, and a culture that produces genuinely exceptional science. And yet, when it comes to scaling that science into sustainable commercial businesses, the UK consistently falls short.
This isn't just an abstract economic problem. For anyone hiring in UK life sciences (or looking for a new role in the sector) understanding this structural tension matters.
The numbers tell an uncomfortable story
Here's a striking data point: approximately 42% of graduates in the UK hold STEM degrees, compared to just 19% in the US. And yet only around 0.8% of UK workers are employed in the life science sector, versus 1.4% in the US. The US has half the proportion of STEM graduates - but nearly twice the percentage of its workforce in life sciences. Something is clearly going wrong in the pipeline between education and employment.
I believe that part of this is a visibility problem. Young people making career decisions often have a narrow image of what a scientist actually does. The word conjures lab coats and bench work, but while that's a vital part of the sector, it's only one part. Medical science liaisons, clinical development professionals, commercial planners, regulatory affairs specialists, business development directors are all science-related careers, but they're rarely labelled that way in the public consciousness.
The clinician crossover gap
One specific area where the UK lags behind the US is the movement of clinicians into industry. In the US, physicians are much more aware of and comfortable with the idea of moving sponsor-side - into roles as medical directors, chief medical officers, or clinical development leads. The career pathways are established and culturally accepted.
In the UK, that crossover happens far less. Clinicians who might thrive in drug development roles often simply aren't aware that the path exists. The result is that US companies pay substantial premiums to bring physicians into development roles, while UK companies struggle to fill equivalent positions.
The scaling capital problem
The branding issue, while significant, sits on top of a deeper structural challenge. As Kaiser puts it directly: "The UK excels at creating companies and world-class science early-stage but lacks the infrastructure for scaling compared to the US."
The UK is genuinely good at starting companies and doing early-stage science. The problem is that when it's time to grow, the capital infrastructure - large-scale venture funds, deep pools of growth equity, institutional investors with the risk appetite for long development timelines - is thinner than in the US. The consequence, as Kaiser observes, is stark: "UK biotechs often bring in US investors or VCs, resulting in US ownership of UK science - which represents a loss of UK science and offshoring of intellectual property."
That pattern of UK science / US ownership is common and represents a genuine structural loss for the domestic ecosystem. It's not a criticism of the companies or investors involved; it's a rational response to where the capital is. But it's a problem that won't fix itself.
So, what would actually help?
I think there are a few key considerations here: greater investment in career pathways from STEM education into commercial life sciences roles would start to address the pipeline issue. Targeted programmes that help clinicians understand and access industry opportunities would begin to close the crossover gap. And sustained commitment to building the scale-up capital infrastructure would, over time, change the conditions under which UK companies grow.
Ultimately, the underlying science is not the problem, but I believe the ecosystem that should carry it from discovery to scale is.
Scaling a life sciences team in the UK comes with unique challenges, but the right recruitment partner can make a significant difference. Whether you're building from scratch or strengthening an existing function, I have the network and sector knowledge to support you. Get in touch with me to discuss your current requirements.
____________________________________________________________________________________________________________________
Michael Woodhead Associate Director, Consult Search
Michael has been recruiting in the life sciences sector for seven years, specialising in building teams across biometrics, clinical development, research, and medical affairs. His focus spans senior individual contributors through to leadership level, with particular depth in biostatistics, statistical programming, and data management. Prior to life sciences, Michael spent five years recruiting across technical industries. He works with biotech, biopharma, and CRO clients across the United States and Europe.
Kaiser Karamdad Life Sciences Commercial Strategy Specialist
Kaiser holds a PhD from Imperial College London in synthetic biology and chemical biology, and has spent his career at the intersection of science and commercial strategy. He began at Cambridge Healthcare Research, supporting pharma and biotech clients on commercial planning and business development, before moving into industry as Chief of Staff to the CEO at Achilles Therapeutics - a cell therapy company that IPO'd on NASDAQ in 2021. Most recently, Kaiser served as BD Director at Quell Therapeutics, a CAR-Treg focused cell therapy company, where he led partnering strategy and commercial value proposition. He is currently exploring his next opportunity in business development and commercial leadership within the life sciences sector.